Arrowstreet Capital Limited Partnership lifted its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 27.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,687,347 shares of the medical equipment provider's stock after buying an additional 361,539 shares during the quarter. Arrowstreet Capital Limited Partnership owned approximately 0.75% of Hologic worth $121,641,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also modified their holdings of the stock. Brooklyn Investment Group grew its holdings in Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock worth $82,000 after acquiring an additional 145 shares during the period. Smartleaf Asset Management LLC boosted its stake in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the period. Trivant Custom Portfolio Group LLC increased its stake in Hologic by 2.1% in the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock valued at $602,000 after buying an additional 169 shares during the period. UMB Bank n.a. lifted its holdings in shares of Hologic by 4.1% during the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock valued at $343,000 after buying an additional 188 shares during the last quarter. Finally, Capital Investment Counsel Inc raised its holdings in Hologic by 3.6% during the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock valued at $413,000 after buying an additional 200 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.
Hologic Price Performance
NASDAQ:HOLX traded up $0.78 during trading hours on Thursday, reaching $61.34. The stock had a trading volume of 1,769,565 shares, compared to its average volume of 1,811,059. The stock has a market capitalization of $13.76 billion, a PE ratio of 19.34, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 52 week low of $58.38 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The company has a 50 day moving average price of $64.69 and a two-hundred day moving average price of $72.88.
Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several brokerages have issued reports on HOLX. William Blair reissued an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Morgan Stanley cut their price objective on Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Finally, Raymond James restated an "outperform" rating and set a $90.00 price objective (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $84.62.
Read Our Latest Analysis on Hologic
Hologic Company Profile
(
Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Featured Articles
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
